U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417566) titled 'A Study of DC6001 Tablet in Healthy Chinese Adult Subjects' on Feb. 11.
Brief Summary: This study adopts a randomized, double-blind, parallel placebo-controlled dose-escalation design, consisting of two parts: Part 1 includes a single ascending dose (SAD) study plus a food effect (FE) study, and Part 2 is a multiple ascending dose (MAD) study.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Stargardt Disease
Intervention:
DRUG: DC6001
DC6001 tablet
DRUG: Placebo
DC6001 placebo tablet
Recruitment Status: RECRUITING
Sponsor: Heronova Pharmaceuticals
Disclaimer: Curated by HT Syndication....